Mirum Pharmaceuticals ((MIRM)) has held its Q2 earnings call. Read on for the main highlights of the call.

Summer Sale - Claim 70% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Mirum Pharmaceuticals’ latest earnings call struck an upbeat tone, underscored by strong revenue growth, expanding margins and a reinforced balance sheet. Management highlighted a rich slate of upcoming clinical and regulatory milestones that could further transform the business, while acknowledging that new regulatory hurdles in PSC introduce meaningful uncertainty that investors will need to monitor closely.

Strong Quarterly Revenue Growth

Mirum reported Q2 2026 net product sales of $176.0M, up from $128.0M a year earlier for a 37.5% YoY increase. Executives credited broad portfolio demand and effective commercial execution, signaling that the company’s rare‑disease franchise is gaining traction across both established and newer treatment markets.

Raised Full-Year Sales Guidance

On the back of the robust quarter, Mirum lifted its 2026 net product sales guidance to a range of $680M–$700M. The higher outlook reflects confidence in sustained demand for existing medicines and the company’s ability to maintain growth momentum as its therapies penetrate global markets.

Livmarli and Bile Acid Portfolio Strength

Livmarli remains Mirum’s commercial engine, generating $129M in Q2 sales, with $92M from the U.S. and $37M from international markets. Bile acid medicines added roughly $48M, helped by increased adult PFIC diagnosis and expanding reimbursement abroad, supporting management’s case for Livmarli’s long‑term blockbuster potential.

Balance Sheet Reinforced by Convertible Notes

Mirum closed the quarter with $561M in cash, cash equivalents and investments, up from $391M at the start of the year. The company issued $690M of 0% convertible notes, netting $672M, and used part of the proceeds to settle 75% of its 2029 notes, adding $197M in cash and reducing future interest expense while posting positive operating cash flow.

Commercial Margin Expansion

The commercial cash contribution margin reached the high‑50s percent in the first half of 2026, an improvement of about 5 percentage points versus the prior year. Management framed this margin expansion as evidence that scaling the rare‑disease portfolio is beginning to deliver stronger profitability, even as the company continues to invest heavily in growth initiatives.

Pipeline Momentum and Near-Term Catalysts

Investors heard a detailed update on Mirum’s pipeline, with several catalysts approaching. Zilurgisertib faces a September PDUFA and could launch in the U.S. in Q4, while EU filings are already submitted, and volovitug’s AZURE‑1 and AZURE‑4 readouts this year may support a potential BLA in H1 2027 alongside EXPAND and MRN‑338 data.

Regulatory Recognition for Volixibat in PSC

The company emphasized that VISTAS, testing volixibat in PSC‑related cholestatic pruritus, met its primary endpoint and won Breakthrough Therapy designation from regulators. That status reflects recognition of volixibat’s potential to address a significant unmet need for PSC patients suffering from severe itching, an area with limited current options.

Phase 3 Requirement Delays PSC Timeline

Despite the positive data, Mirum disclosed that a pre‑NDA meeting led regulators to recommend a Phase 3 study for volixibat in PSC. As a result, the company has pushed its planned NDA submission back to the first half of 2027, introducing added execution risk and delaying expected PSC commercialization compared with earlier plans.

Uncertainty Around PSC NDA Package

Management stressed that VISTAS delivered statistically and clinically persuasive results but admitted they are not yet aligned with regulators on what constitutes an acceptable NDA package. This lack of clarity could require further data or extended dialogue and leaves the PSC pathway as a key overhang amid otherwise strong corporate momentum.

Elevated Operating Expenses and R&D Investment

Q2 operating expenses totaled $290M, including $16M of in‑process R&D tied to the Zilurgisertib license and $76M of R&D, with $29M devoted to volovitug. SG&A reached $66M, cost of sales $23M and noncash items such as stock‑based compensation and amortization added $37M, reflecting Mirum’s willingness to spend aggressively to build and diversify its pipeline.

PSC Revenue Timing Pushed Out

The revised regulatory path for volixibat means potential PSC revenue will arrive later than previously envisioned. While core products continue to grow, investors should factor in that PSC‑related contributions are now unlikely to materialize before 2027, increasing near‑term uncertainty around that particular indication.

Forward-Looking Guidance and Outlook

Looking ahead, Mirum’s raised 2026 sales guidance and strong cash position underpin a confident outlook, even as expenses remain high. The company is preparing for a possible Q4 launch of Zilurgisertib, multiple key readouts for volovitug, EXPAND and VANTAGE into 2027, and early proof‑of‑concept data for MRN‑338, setting up a catalyst‑rich period for shareholders.

Mirum’s earnings call painted a picture of a company balancing strong commercial performance with ambitious clinical goals, tempered by regulatory friction in PSC. For investors, the story remains one of solid growth, rising margins and a deep pipeline, with the main watch point centered on how effectively management navigates the PSC setback and converts upcoming milestones into durable revenue.